Golcadomide plus rituximab shows deep, durable responses in relapsed follicular lymphoma, with manageable neutropenia and limited added toxicity.
Daniel Morillo, MD
Advertisement
Articles by Daniel Morillo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CMS Proposes Cut to 340B Drug Payments in 2027 Outpatient Rule
2
Further MonumenTAL-3 Follow-Up Needed for Triplet Regimen in Relapsed Myeloma
3
Oncologists Consider Treatment Duration and New Options in Progressive Desmoid Tumors
4
Adagrasib Plus Cetuximab Falls Short in KRAS G12C–Mutated Colorectal Cancer
5